BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright lowered their price objective on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th.

BioLineRx Trading Down 3.9 %

BLRX opened at $0.11 on Monday. BioLineRx has a 1-year low of $0.08 and a 1-year high of $1.44. The firm has a 50-day moving average price of $0.22 and a two-hundred day moving average price of $0.47. The stock has a market capitalization of $8.39 million, a PE ratio of -0.48 and a beta of 1.46. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11.

BioLineRx’s stock is set to reverse split before the market opens on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 29th.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. As a group, equities analysts anticipate that BioLineRx will post -0.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. PVG Asset Management Corp bought a new position in BioLineRx Ltd. (NASDAQ:BLRX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned 0.15% of BioLineRx as of its most recent filing with the Securities & Exchange Commission. 1.56% of the stock is owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.